

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

4

Application Number

10/628,734

Filing Date

07/28/2003

First Named Inventor

Jon A. Wolff

Art Unit

1632

Examiner Name

Weitach, Joseph T.

Attorney Docket Number

Mirus.013.03.6

**RECEIVED  
CENTRAL FAX CENTER****JAN 11 2007****ENCLOSURES (Check all that apply)**

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/  
Incomplete ApplicationReply to Missing Parts  
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition



Petition to Convert to a



Provisional Application



Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_



Landscape Table on CD

Remarks



After Allowance Communication to TC

Appeal Communication to Board  
of Appeals and InterferencesAppeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify  
below):**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

Mirus Bio Corporation

Signature



Printed name

Kirk Ekena

Date

01/11/2007

Reg. No.

56,672

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature



Typed or printed name

Kirk Ekena

Date

01/11/2007

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED  
CENTRAL FAX CENTER

JAN 11 2007

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/628,734  
Applicants : Jon A. Wolff et al  
Filed : 07/28/2003  
Art Unit : 1632  
Examiner : Wolfach, Joseph T.  
Docket No. : Mirus.013.03.6

For: Intravascular Delivery of Non-Viral Nucleic Acid

Commissioner of Patents  
PO Box 1450  
Alexandria, VA 22311-1450

INFORMATIONAL STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.56, applicant hereby calls to the attention of the Patent and Trademark Office the publications listed on the attached PTO 1449.

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

US patent documents

Patent No.	Applicant	Publication date
US-2002/132788	Lewis et al.	09/19/2002
US-2002/137707	Monahan et al.	09/26/2002
US-2001/004636	Monahan et al.	06/21/2001
US-6,265,387	Wolff et al.	07/24/2001

RECEIVED  
CENTRAL FAX CENTER


JAN 11 2007

Foreign patent documents

Patent No.	Applicant	Publication date
WO 00/15285	Mirus Corp.	03/23/2000
WO 00/50617	Mirus Corp.	08/31/2000

Applicant respectfully requests that these publications be expressly considered during the prosecution of this application and made of record herein and appear among the 'References Cited' on any patent to issue herefrom.

Respectfully submitted,



Kirk Ekena, Reg. No. 56,672  
Mirus Bio Corporation  
505 South Rosa Road  
Madison, WI 53719  
608-238-4400

I hereby certify that this correspondence is facsimile  
transmitted to the USPTO on this date: 01/11/2007



Kirk Ekena

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**JAN 11 2007**